

1645

RECEIVED
SEP 11 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Varshavsky et al.

Serial No: 09/923,917

Filed: August 6, 2001

For: Split-Ubiquitin Based Reporter Systems
and Methods of Their Use

Attorney Docket No. GPCG-P01-017


Art Unit: 1645

Examiner: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

August 29, 2002
Date of Signature
and of Mail Deposit


Brent LaBarge

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

PRELIMINARY AMENDMENT

Please amend the above-identified application prior to substantive examination as follows:

IN THE SPECIFICATION:

- On Pages 117 and 118, please replace the second and first partially complete paragraphs respectively with the following text:

The Cub-RURa3 reporter module was constructed by PCR amplification. The fragment covered residues 35-76 of UBI4 and a Sall and BamHI site to bring the fragment in front of the LACI-URA3 gene fusion (Ghislain et al., 1996). The sequence between the C terminus of Cub and the LACI sequence of the RURA3 reads: **GGT GGT AGG CAC** GGA TCC (SEQ ID NO: 1). The last two residues of the Cub and the N-terminal arginine of the RURA3 are printed in bold letters; the BamHI site is underlined. SEC63-Cub-RURA3 was constructed by PCR amplification of the last 445 base pairs (bp) of the coding sequence of SEC63 not including the stop codon by using genomic DNA of *S. cerevisiae* as a template. The ends of the PCR product